Emerging Cancer Therapy: Microbial Approaches and Biotechnological Tools

Cancer therapy remains a challenge despite the huge changes and improvements we have made in the scientific and engineering tools that we use. Emerging Cancer Therapy explores the potential and actual uses of live bacteria or their products in the treatment of cancer. Providing a state–of–the–art overview of this field, this book breaks new ground in emerging cancer treatment modalities. Microbes that are currently and can potentially be used therapeutically and their products are reviewed in detail, and studies involving clinical trials and evaluation with these anticancer agents are addressed.

Spis treści:
Foreword (Arsénio M Fialho and Ananda M Chakrabarty).
SECTION I Live/attenuated bacteria and viruses as anticancer agents.
Chapter 1: Salmonella typhimurium mutants selected to grow only in tumors and eradicate them in nude mouse models (Robert M. Hoffman).
Chapter 2: The use of living Listeria monocytogenes as an active immunotherapy for the treatment of cancer (John Rothman1, Anu Wallecha1, Paulo Cesar Maciag1, Sandra Riviera, Vafa Shahabi,and Yvonne Paterson).
Chapter 3: Bacillus Calmete–Guerin (BCG) for urothelial carcinoma of the bladder (Timothy P. Kresowik and Thomas S. Griffith).
Chapter 4: Live clostridia: a powerful tool in tumor biotherapy (Lieve Van Mellaert, Ming Q Wei and Jozef Annné).
Chapter 5: Bifidobacterium as a delivery system of functional gene for cancer gene therapy (Geng–Feng Fu, Yan Yin, Bi Hu and Gen–Xing Xu).
Chapter 6: Replication selective viruses for the treatment of cancer (Padma Sampath and Steve H. Thorne).
Chapter 7: Engineering Herpes simplex virus for cancer oncolytic virotherapy (Jason S. Buhrman, Tooba A. Cheema and Giulia Fulci).
SECTION II Bacterial products as anticancer agents.
Proteins/Peptides.
Chapter 8: Promiscuous Anticancer Drugs from Pat hogenic Bacteria: Rational versus Intelligent Drug Design (Arsénio M Fialho and Ananda M. Chakrabarty).
Chapter 9: Arginine Deiminase and Cancer Therapy (L. Feun, M.T. Kuo, M. You, C Wu, M. Wangpaichitr and N. Savaraj).
Chapter 10: Cytosine deaminase/5–fluorocytosine molecular cancer chemotherapy (Sergey A. Kaliberov and Donald J. Buchsbaum).
Chapter 11: Bacterial proteins against metastasis (A.M.E.Walenkamp).
Immunotoxins.
Chapter 12: Pseudomonas Exotoxin A based immunotoxins for targeted cancer therapy (Philipp Wolf and Ursula Elsässer–Beile).
Chapter 13: Denileukin Diftitox in Novel Cancer Therapy (Lin–Chi Chen and Nam H. Dang).
Cationic Peptides.
Chapter 14: The Application of Cationic Antimicrobial Peptides in Cancer Treatment: Laboratory Investigations and Clinical Potential (Ashley Hilchie and David W. Hoskin).
Other products.
Chapter 15: Prodiginines and their potential utility as proapoptotic anticancer agents (Neil R. Williamson, Suresh Chawrai, Finian J. Leeper and George P. C. Salmond).
Chapter 16: Farnesyltransferase inhibitors of microbial origins in cancer therapy (Jingxuan Pan and Sai–Ching Jim Yeung).
Chapter 17: The use of RNA and CpG DNA as nucleic acid–based therapeutics (Jörg Vollmer).
SECTION III Patents on bacteria/bacterial products as anticancer agents.
Chapter 18: The Role and Importance of Intellectual Property Generation and Protection in Drug Development (Arsénio M Fialho and Ananda M. Chakrabarty).